Skip to content

What Really Happens to Estrogen in Your Body (And Why It Matters More Than Your Lab Number)

picture of a woman holding a menstrual cup, wondering about estrogen metabolism, liver detoxification stages and steps to remove excess estrogen and fix estrogen dominance

You may already know that estrogen dominance isn’t really about having “too much” estrogen. It’s about how much estrogen you have compared to your progesterone, DHEAs, and testosterone, and just as importantly, how well your body gets rid of the estrogen it makes or estrogen metabolism. If you are a menstruating person, your body’s main form of estrogen, estradiol, rises from as low as about 75 pmol/L to a peak at ovulation of about 1500 pmol/L, and then falls back down for your next period to start.

Contents show

That second part is the piece almost nobody explains: estrogen doesn’t just leave your body on its own. Estrogen metabolism means estrogen must be broken down and processed, step by step, mainly by your liver and gut. How well that process works can matter just as much as how much estrogen you’re producing in the first place. Two people can have the exact same estrogen blood level and feel completely different, because the real difference isn’t how much estradiol they make; it’s what their bodies do with it afterward.

Estrogen Metabolism: It Doesn’t Just “Leave.”

Think of estrogen metabolism like a disassembly line, with three main stations. Your liver and gut break estrogen down (Station 1), neutralize it so it’s no longer active (Station 2), and then physically remove it from your body (Station 3). All three stations need to function properly and in sequence for efficient estrogen metabolism. If any one station gets backed up, estrogen (or its byproducts) can build up or be reabsorbed, even if your blood test looks “normal,” because these byproducts aren’t measured in your estradiol blood test. These byproducts can retain estrogen activity, even though they are no longer estradiol.

Step 1: Breaking Estrogen Down – Three Possible Routes

When your liver starts estrogen metabolism, it sends it down one of three different paths. Which path it takes matters, because the end products aren’t all the same.

One estrogen metabolism path is the more favourable one. This route produces a byproduct that’s relatively mild and generally considered the “friendlier” option.

A second path produces a byproduct that’s more strongly estrogen-like. This is the route most associated with the classic symptoms of too much estrogen – heavy periods, breast tenderness, polyps, endometriosis, and fibroid growth.

A third path for estrogen metabolism is the one researchers have studied most closely for safety. This route can produce a reactive byproduct that, if not properly neutralized in Step 2, can directly damage DNA. This is one of the more consistently demonstrated findings in the research on how estrogen can contribute to cell damage over time, and it’s a meaningful part of why the next step in this process, neutralizing those byproducts, matters so much.

An important note on something you may have read about online. A lot of wellness content talks about a specific “ratio” between the first two pathways above, as if it were a proven, reliable way to predict breast cancer risk.

The honest picture is more nuanced than that. Several large research studies have looked for this connection and found the link was weak at best, or didn’t hold up at all, even though the underlying biology makes sense on paper. I’d rather tell you that plainly than oversell a number that the research itself hasn’t confirmed. What does have stronger, more consistent research support is the third pathway above, the one that can produce a reactive byproduct, which is exactly why Step 2 (neutralizing it) is the part of this process worth paying the most attention to.

Step 2: Neutralizing the Byproducts So They Can Be Safely Removed

Once estrogen has been broken down in Step 1, it isn’t ready to leave your body yet; in some cases, it’s actually more reactive than before. Step 2 is where your liver “tags” these byproducts to make them stable and water-soluble, so they can be safely flushed out in urine or stool, rather than left to circulate or cause irritation.

The most important part of this step is an estrogen metabolism process called methylation, essentially attaching a small molecular “tag” to the more reactive estrogen metabolism byproducts (especially the one from the third pathway above) to deactivate them before they can cause any damage. This is one of the most clinically meaningful steps in the entire process of estrogen metabolism because it’s the difference between a byproduct being safely neutralized and left active.

Your body also has two other tagging systems running in parallel – one that attaches a sugar-based tag, and one that attaches a sulphate-based tag – both of which make estrogen byproducts water-soluble enough to be excreted through bile (stool) and urine.

Why “MTHFR” Matters Here (and Why I Won’t Overstate It)

You may have heard of MTHFR, a gene that affects how well your body processes folate or folic acid. Here’s the connection: the methylation “tagging” step above runs on a specific fuel source (active folic acid known as L-5MTHF), and your MTHFR gene plays a role in how efficiently your body produces that fuel from folate.

A common variation in the MTHFR gene means some people produce this fuel less efficiently, which, in theory, could lead to a slower or less complete tagging step. This is the reasoning behind why naturopathic and functional practitioners often pay attention to MTHFR in patients with estrogen-related symptoms.

I want to be straightforward about the evidence here, though: research on MTHFR and breast cancer risk specifically has been mixed – some studies have hinted at a connection under certain conditions, while others, including a large analysis of over 34,000 breast cancer cases, found the related gene variations weren’t reliably linked to risk on their own.

So I don’t present MTHFR status as a verdict or a diagnosis. What it does tell us is whether one specific step in this process might need extra support, which is exactly the kind of thing that responds well to targeted nutrients (specifically, the active, body-ready forms of folate, B12, and B6, rather than synthetic folic acid, which people with this gene variation tend to process less efficiently).

Step 3: Getting Estrogen Out of Your Body for Good – Why Your Gut Matters

This is the step almost no one talks about, and it might be the most actionable one in estrogen metabolism.

Once estrogen byproducts are “tagged” in Step 2, they travel through bile into your intestines to be eliminated. But here’s the catch: certain gut bacteria produce an enzyme that can actually untag those byproducts, which frees the estrogen to be reabsorbed into your bloodstream instead of leaving your body. Researchers call this collection of gut bacteria your “estrobolome.” In plain terms: if your gut bacteria are out of balance, estrogen that your liver already worked to process can get sent right back into circulation instead of being eliminated.

This is genuinely a newer, still-developing area of research, and scientists are still working out exactly which bacteria matter most. But it already has real clinical relevance; for example, a 2025 review on this topic specifically connected gut imbalances to higher risk of endometriosis and related fertility difficulties, which tells you this isn’t just about cancer risk; it’s relevant to many estrogen-related conditions.

One supplement, calcium-D-glucarate, works specifically at this step. It blocks the “untagging” enzyme from gut bacteria, helping the estrogen byproducts your liver already processed actually make it out of your body instead of being recycled back in. The mechanism behind it is well understood; large-scale confirmatory human trials remain limited, so I treat it as a reasonable, biologically sound tool for estrogen metabolism rather than a guaranteed fix.

Why a Standard Blood Test for Estrogen Doesn’t Tell the Whole Story

A typical blood test for estradiol gives you one number, for one form of estrogen, at one moment in time. What it can’t tell you is which of the three pathways above your estrogen metabolism is taking, whether your “tagging” step (Step 2) is keeping up, or whether your gut is sending already-processed estrogen back into circulation (Step 3). This is exactly the gap that a urine-based hormone test, most commonly called the DUTCH test (Dried Urine Test for Comprehensive Hormones), is designed to fill.

This isn’t a fringe method. A peer-reviewed study comparing dried urine samples with standard blood tests found that the dried urine method holds up well and is genuinely useful for assessing hormone-related conditions. The simplest way to think about the difference: a blood test tells you what’s circulating right now; a urine metabolite test tells you what your body has actually been doing with that hormone as it is trying to clear it through the liver.

What this kind of estrogen metabolism testing can show you that a standard blood panel can’t:

  • Which of the three breakdown pathways your liver is favouring
  • How well your “tagging” (methylation) step is keeping up
  • Your liver’s estrogen metabolism processing over a full day, rather than a single snapshot

This kind of testing doesn’t replace a standard hormone blood panel; it adds information blood testing was never designed to capture. For patients who have classic estrogen-dominance symptoms but “normal” bloodwork, this is very often where the missing piece is. It’s worth knowing up front that this test isn’t covered by OHIP, though some extended health benefit plans do cover all or part of it.

Hidden Sources of Extra Estrogen: What’s an “Endocrine Disruptor”?

So far, this has all been about estrogen metabolism of estradiol that your own body makes. But there’s a second category worth understanding: chemicals in everyday products that act like estrogen once they’re in your body. These are sometimes called xenoestrogens or endocrine disruptors, and three of the most common, well-studied examples are BPA, phthalates, and parabens.

BPA, found in many plastics and the lining of canned food, is able to attach to the same receptors estrogen uses in your cells. For a long time, it was assumed to be a “weak” estrogen mimic and therefore not a big concern, but research has shown it can actually trigger just as strong a hormonal response as your body’s own estrogen, sometimes even at very low exposure levels, because it can activate hormone signalling through more than one route in your cells.

Phthalates, used to make plastics flexible and often hidden in personal care products under the ingredient “fragrance,” can also bind to hormone receptors in the body, including the same ones estrogen uses.

Parabens, common preservatives in cosmetics, lotions, shampoos, and sunscreens, work the same way. They’ve been shown in lab studies to attach to estrogen receptors and even encourage the growth of estrogen-sensitive breast cells.

Common everyday sources to be aware of:

  • Canned foods, plastic water bottles, and store receipts (BPA)
  • Vinyl products, scented personal care items, and soft plastic packaging, often hidden under “fragrance” on the label (phthalates)
  • Cosmetics, lotions, and shampoos listing methylparaben, propylparaben, or butylparaben on the ingredient list
  • Conventionally grown produce with higher pesticide residue, some of which can also act like estrogen in your body

Why this matters for everything above: these chemicals increase your total estrogen exposure before your liver and gut even process it. So even a body that’s clearing estrogen perfectly well through the three steps above still has more work to do if daily exposure to these chemicals is high. Reducing exposure and supporting your body’s ability to process work together; neither one replaces the other.

Estrogen Dominance Symptom Checklist

If you’re checking your own symptoms against this list, having several symptoms from more than one category below is a stronger signal than one or two on their own.

Menstrual & reproductive symptoms of estrogen dominance

Breast symptoms of sluggish estrogen metabolism

  • Breast tenderness, swelling, or fullness, especially before your period
  • Lumpy or dense-feeling breast tissue

Mood & thinking symptoms of estrogen dominance

  • Increased anxiety or irritability tied to your cycle
  • Tearful, weepy-type PMS
  • Depression that worsens before your period
  • Brain fog

Headaches can be signs of sluggish estrogen metabolism

Skin & weight

  • Hormonal acne, especially along the jawline
  • Unexplained weight gain, particularly around the hips and thighs
  • Fluid retention and bloating

Other symptoms of sluggish estrogen metabolism

  • Low libido
  • Fatigue that doesn’t improve with sleep

This checklist is meant to help you notice patterns, not to diagnose yourself. Confirming whether estrogen dominance is actually behind your symptoms takes a proper history and the right testing; see the testing section above.

Conditions Linked to Estrogen Dominance

Several common conditions share too much estrogen (relative to progesterone) as part of what’s driving them. The strength of that connection varies by condition, and estrogen metabolism is rarely the only factor, but it’s consistently part of the picture.

Uterine fibroids. Fibroids have long been described as estrogen-driven, though current research suggests progesterone is actually the more direct fuel for their growth, with estrogen’s role being to prepare the tissue so progesterone can act on it. Either way, both hormones are involved, which is why addressing estrogen metabolism alone often isn’t the full answer.

Endometriosis. This is fundamentally an estrogen-driven, inflammatory condition. As mentioned above, newer research is also connecting gut bacteria imbalances specifically to endometriosis and related fertility struggles, which ties this condition directly back to the gut-related Step 3 discussed earlier in this article.

Fibrocystic breast changes. These benign, often uncomfortable breast changes are closely tied to the balance between estrogen and progesterone. Conditions that shift that balance toward more estrogen, including PCOS, have been shown to meaningfully raise the risk of developing these changes.

Heavy periods. Heavy menstrual bleeding is one of the most direct results of poor estrogen metabolism, since estrogen drives the buildup of your uterine lining, and it’s progesterone’s job to balance that out and allow it to shed in a moderate way each cycle.

PCOS (in some women). Not everyone with PCOS has estrogen dominance. PCOS shows up differently from person to person. But for women whose PCOS involves irregular or absent ovulation, estrogen keeps being produced without the progesterone surge that ovulation normally triggers, which can create the same kind of unopposed estrogen exposure described throughout this article.

What This Means for Estrogen Metabolism Treatment

The right approach depends on exactly where your body’s process is getting stuck, which is exactly why testing is so much more useful than guessing. If your “tagging” step (Step 2) needs support, that means the active, body-ready forms of folate, B6, and B12, not synthetic folic acid, especially if MTHFR is part of your picture. If your liver needs help shifting estrogen toward the more favourable breakdown pathway, indole-3-carbinol (found in cruciferous vegetables) or its concentrated form, DIM, has clinical research behind it for doing exactly that. And if your gut is sending already-processed estrogen back into circulation (Step 3), that’s where calcium-D-glucarate and addressing gut bacteria imbalances become relevant.

This is also why generic “liver detox” kits built around dandelion and milk thistle usually fall short

Liver detox kits don’t actually target the tagging step or the gut-recycling step that this whole process depends on. Real estrogen metabolism support means identifying which station in this three-step system needs help, and giving your body exactly that.

Estrogen Metabolism Research

  1. Stanczyk FZ. The 2-/16α-Hydroxylated Estrogen Ratio-Breast Cancer Risk Hypothesis: Insufficient Evidence for its Support. J Steroid Biochem Mol Biol. 2020 Jul;201:105685. doi: 10.1016/j.jsbmb.2020.105685. Epub 2020 Apr 19. PMID: 32320758..
  2. Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schünemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology. 2000 Nov;11(6):635-40. doi: 10.1097/00001648-200011000-00004. PMID: 11055622.
  3. Obi N, Vrieling A, Heinz J, Chang-Claude J. Estrogen metabolite ratio: Is the 2-hydroxyestrone to 16α-hydroxyestrone ratio predictive for breast cancer? Int J Womens Health. 2011 Feb 8;3:37-51. doi: 10.2147/IJWH.S7595. PMID: 21339936; PMCID: PMC3039007.
  4. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2029-35. doi: 10.1158/1055-9965.EPI-08-0262. PMID: 18708395; PMCID: PMC2562592.
  5. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol. 1996;36:203-32. doi: 10.1146/annurev.pa.36.040196.001223. PMID: 8725388.
  6. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, Sutter T. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta. 2006 Aug;1766(1):63-78. doi: 10.1016/j.bbcan.2006.03.001. Epub 2006 Apr 19. PMID: 16675129.
  7. E.L. Cavalieri, D.E. Stack, P.D. Devanesan, R. Todorovic, I. Dwivedy, S. Higginbotham, S.L. Johansson, K.D. Patil, M.L. Gross, J.K. Gooden, R. Ramanathan, R.L. Cerny, & E.G. Rogan, Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumour initiators, Proc. Natl. Acad. Sci. U.S.A. 94 (20) 10937-10942, https://doi.org/10.1073/pnas.94.20.10937 (1997).
  8. Liehr JG. Genotoxic effects of estrogens. Mutat Res. 1990 May;238(3):269-76. doi: 10.1016/0165-1110(90)90018-7. PMID: 2160607.
  9. Almeida M, Soares M, Fonseca-Moutinho J, Ramalhinho AC, Breitenfeld L. Influence of Estrogenic Metabolic Pathway Genes Polymorphisms on Postmenopausal Breast Cancer Risk. Pharmaceuticals (Basel). 2021 Jan 27;14(2):94. doi: 10.3390/ph14020094. PMID: 33513690; PMCID: PMC7910923.
  10. Qin X, Peng Q, Qin A, Chen Z, Lin L, Deng Y, Xie L, Xu J, Li H, Li T, Li S, Zhao J. Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis. Diagn Pathol. 2012 Oct 8;7:136. doi: 10.1186/1746-1596-7-136. PMID: 23039364; PMCID: PMC3543196.
  11. Lin WY, Chou YC, Wu MH, Huang HB, Jeng YL, Wu CC, Yu CP, Yu JC, You SL, Chu TY, Chen CJ, Sun CA. The MTHFR C677T polymorphism, estrogen exposure and breast cancer risk: a nested case-control study in Taiwan. Anticancer Res. 2004 Nov-Dec;24(6):3863-8. PMID: 15736423.
  12. Bergman-Jungeström M, Wingren S. Catechol-O-Methyltransferase (COMT) gene polymorphism and breast cancer risk in young women. Br J Cancer. 2001 Sep 14;85(6):859-62. doi: 10.1054/bjoc.2001.2009. PMID: 11556837; PMCID: PMC2375076.
  13. Newman M, Pratt SM, Curran DA, Stanczyk FZ. Evaluating urinary estrogen and progesterone metabolites using dried filter paper samples and gas chromatography with tandem mass spectrometry (GC-MS/MS). BMC Chem. 2019 Feb 4;13(1):20. doi: 10.1186/s13065-019-0539-1. PMID: 31384769; PMCID: PMC6661742.
  14. Lucas A, Herrmann S, Lucas M. The role of endocrine-disrupting phthalates and bisphenols in cardiometabolic disease: the evidence is mounting. Curr Opin Endocrinol Diabetes Obes. 2022 Apr 1;29(2):87-94. doi: 10.1097/MED.0000000000000712. PMID: 35034036; PMCID: PMC8915988.
  15. Li Y, Yang H, He W, Li Y. Human Endocrine-Disrupting Effects of Phthalate Esters through Adverse Outcome Pathways: A Comprehensive Mechanism Analysis. Int J Mol Sci. 2023 Aug 31;24(17):13548. doi: 10.3390/ijms241713548. PMID: 37686353; PMCID: PMC10488033.
  16. Alonso-Magdalena P, Ropero AB, Soriano S, García-Arévalo M, Ripoll C, Fuentes E, Quesada I, Nadal Á. Bisphenol-A acts as a potent estrogen via non-classical estrogen-triggered pathways. Mol Cell Endocrinol. 2012 May 22;355(2):201-7. doi: 10.1016/j.mce.2011.12.012. Epub 2011 Dec 31. PMID: 22227557.
  17. Hafezi SA, Abdel-Rahman WM. The Endocrine Disruptor Bisphenol A (BPA) Exerts a Wide Range of Effects in Carcinogenesis and Response to Therapy. Curr Mol Pharmacol. 2019;12(3):230-238. doi: 10.2174/1874467212666190306164507. PMID: 30848227; PMCID: PMC6864600.
  18. Pan S, Yuan C, Tagmount A, Rudel RA, Ackerman JM, Yaswen P, Vulpe CD, Leitman DC. Parabens and Human Epidermal Growth Factor Receptor Ligand Cross-Talk in Breast Cancer Cells. Environ Health Perspect. 2016 May;124(5):563-9. doi: 10.1289/ehp.1409200. Epub 2015 Oct 27. PMID: 26502914; PMCID: PMC4858398.
  19. Yerushalmi R, Bargil S, Ber Y, Ozlavo R, Sivan T, Rapson Y, Pomerantz A, Tsoref D, Sharon E, Caspi O, Grubsrein A, Margel D. 3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial. Carcinogenesis. 2020 Oct 15;41(10):1395-1401. doi: 10.1093/carcin/bgaa050. PMID: 32458980; PMCID: PMC7566319.
  20. Reyes-Hernández OD, Figueroa-González G, Quintas-Granados LI, Gutiérrez-Ruíz SC, Hernández-Parra H, Romero-Montero A, Del Prado-Audelo ML, Bernal-Chavez SA, Cortés H, Peña-Corona SI, Kiyekbayeva L, Ateşşahin DA, Goloshvili T, Leyva-Gómez G, Sharifi-Rad J. 3,3′-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signalling pathways. Cancer Cell Int. 2023 Aug 26;23(1):180. doi: 10.1186/s12935-023-03031-4. PMID: 37633886; PMCID: PMC10464192.
  21. Memorial Sloan Kettering Cancer Center. Calcium Glucarate (integrative medicine monograph). mskcc.org/cancer-care/integrative-medicine/herbs/calcium-glucarate.
  22. Larnder AH, Manges AR, Murphy RA. The estrobolome: Estrogen-metabolizing pathways of the gut microbiome and their relation to breast cancer. Int J Cancer. 2025 Aug 15;157(4):599-613. doi: 10.1002/ijc.35427. Epub 2025 Apr 3. PMID: 40177842; PMCID: PMC12178105.
  23. Saponara S, Scicchitano F, D’Alterio MN, Chilà C, Daniilidis A, Vitale SG, Angioni S. Could the estrobolome have a role in endometriosis pathogenesis and infertility? A systematic review. BMC Womens Health. 2025 Dec 18;26(1):43. doi: 10.1186/s12905-025-04195-z. PMID: 41413507; PMCID: PMC12821278.
  24. Yang Q, Ciebiera M, Bariani MV, Ali M, Elkafas H, Boyer TG, Al-Hendy A. Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocr Rev. 2022 Jul 13;43(4):678-719. doi: 10.1210/endrev/bnab039. Erratum in: Endocr Rev. 2022 Jul 13;43(4):761. doi: 10.1210/endrev/bnac007. Erratum in: Endocr Rev. 2022 Jul 13;43(4):762. doi: 10.1210/endrev/bnac006. PMID: 34741454; PMCID: PMC9277653.
  25. Munro MG, Tchaikovski SN, Murji A. The epidemiology and pathogenesis of uterine fibroids. Int J Gynaecol Obstet. 2025 Dec;171(3):1029-1045. doi: 10.1002/ijgo.70527. Epub 2025 Sep 27. PMID: 41014005; PMCID: PMC13001707.
  26. Dang B, Clewis M, Miles B, Nguyen Q. The effect of polycystic ovarian syndrome on fibrocystic breast changes in postmenopausal women. Proc (Bayl Univ Med Cent). 2024 Feb 1;37(3):432-436. doi: 10.1080/08998280.2024.2308458. PMID: 38628327; PMCID: PMC11017995.